How can I recognise the high-risk cardiovascular patient? The concept of risk by Ker, JA
Atherosclerosis is a chronic, inflammatory disease involving the coronary, carotid
and aortofemoral vascular beds.  The clinical events caused by this process rep-
resent the major cause of death worldwide.1 The lifetime risk for chronic heart
disease (CHD) for men at the age of 40 years is 48.6% (95% CI: 45.8 - 51.3)
and for women 31.7% (95% CI: 29.2 - 34.2).  The concept of risk factors (pres-
ent early in life and associated with increased risk to develop disease) was intro-
duced into clinical medicine by the Framingham Heart Study.2 The major risk fac-
tors are shown in Table I.3 The quantitative relationship between these risk factors
and coronary heart disease has been elucidated by the Framingham Heart Study
and other similar studies.
The Multiple Risk Factor Intervention Trial (MRFIT) has a large registry, nearly 70
times the size of the Framingham Heart Study.  Data from MRFIT revealed that in
men with a total cholesterol > 4.7 mmol/l there were progressive increases in
coronary artery disease (CAD) mortality, as total cholesterol increased with a rel-
ative risk of 3.8 in patients with a cholesterol level > 6.5 mmol/l.4 The growing
worldwide epidemic of type 2 diabetes mellitus has important implications,
because it has been shown that patients with type 2 diabetes and no history of
prior myocardial infarction (MI) were at similar risk of future coronary events as
patients without diabetes but with prior MI.  The term metabolic syndrome has
also been introduced to emphasise the clustering of metabolic abnormalities in
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HOW CAN I RECOGNISE THE
HIGH-RISK CARDIOVASCULAR
PATIENT? THE CONCEPT OF RISK
Cardiovascular disease has become one of the major causes of death, particularly in
affluent and emerging societies. The risk factors predisposing to this disease are now
well known.
Table I. Modifiable risk factors
Modifiable by lifestyle 
• Cigarette smoking of any amount 
• Obesity, especially abdominal obesity 
• Physical inactivity 
Modifiable by drugs and/or lifestyle 
• Lipid disorders: elevated total cholesterol, elevated low-density 
cholesterol and low high-density cholesterol 
• Hypertension: elevation of blood pressure 
• Insulin resistance/diabetes mellitus 
• Homocysteinaemia 
• Inflammation 
• Dysregulated coagulation or fibrinolysis, e.g. increase in 
fibrinogen, increase in PAI-1 
Unmodifiable 
Age, male gender/post-menopausal state, genetics (family history)
patients with an increased risk for car-
diovascular disease.  The metabolic
syndrome is present many years
before the diagnosis of full-blown type
2 diabetes, during which time suffi-
cient vascular damage may have
taken place.




Fig. 1 links risk factors to the athero-
sclerotic process and emphasises the
central role of nitric oxide (NO) and
endothelial dysfunction.5 Endothelial
dysfunction not only initiates the
process of atherosclerosis, but can at
any time precipitate a clinical event
(e.g. acute MI).
GLOBAL RISK ASSESSMENT
Many clinical guidelines recommend
matching the intensity of preventive
therapy to risk.6
ABSOLUTE RISK 
This is defined as the probability, in
per cent, of a person developing coro-
nary heart disease (MI, death) in the
next 10 years.  A point-scoring system
is used for blood pressure, diabetes
mellitus, smoking,  total cholesterol,
etc., which is incorporated into a
matrix, producing a percentage risk.
Various scoring systems are available,
e.g. Framingham Risk Score, European
Risk Score, Sheffield Tables.  Three
categories of absolute risk are identi-
fied in this way:
Category 1
Very high risk. This comprises diag-
nosed CHD or vascular disease in
another vascular bed (carotid, aortic
aneurysm, peripheral arterial disease),
a higher than 20% risk over 10 years
according to the scoring system, or
diabetes mellitus.  Diabetes mellitus,
specifically type 2, is now considered
as a CHD equivalent.
Category 2
Moderate risk. Two or more risk
factors are present, giving a 10-year
risk of 10 - 20% of developing an
event.
Category 3
Low risk. No risk factor or 1 risk
factor is present.  The risk of develop-
ing an event over the next 10 years
may be as low as 5%.
These multiple risk factor scoring sys-
tems predict risk over a relatively short
period (10 years), whereas a single
risk factor may increase risk over the
long term, e.g. a 30-year-old person
with an elevated cholesterol level may
have a low risk over the next 10 years,
but at the age of 65 years may have a
markedly elevated risk compared with
someone with a low cholesterol level
since the age of 30 years.7
Global risk assessment in the
presymptomatic patient
It is now known that the atherosclerot-
ic process begins early in life, as
demonstrated by the following two
autopsy studies:
• The Pathobiological Deter-
minants of Atherosclerosis in
Youth (PDAY) study. This study
showed that even in young people
≤ 19 years of age fatty streaks and
significant raised lesions (fibrous
plaques) were common, and
increased rapidly in prevalence
between the ages of 15 and 34
years.  A positive association was
shown between these lesions and
classic risk factors such as low-den-
sity lipoprotein (LDL) cholesterol.
8
• The Bogalusa Heart Study. In
this study approximately 50% of
autopsy cases aged 2 - 15 years,
and up to 85% of those aged 21 -
39 years, had significant lesions
in their coronary arteries.9
These studies may stress the point that
primary prevention of atherosclerosis
should start in adolescence or even
earlier.  This is a relatively new con-
cept, suggesting that perhaps children
should be the new target group for
intervention.
RELATIVE RISK 
Relative risk is defined as a ratio of
absolute risk in a patient with risk fac-
tors compared with a person without
risk factors.7 The risk is then calculated
comparatively and related to the other
person.  This is a different way in
which to evaluate risk.
NUMBER NEEDED TO TREAT
Another means of risk assessment is
the number needed to treat to achieve
one desirable outcome prevention over
a specific time period.10 The difference
in absolute risk between patients at
risk and those without risk is used for
the calculation.  This method links the
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Fig.1. Pathogenesis of atherosclerotic heart disease.
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person’s absolute risk to the cost-effec-
tiveness of various risk modifications.
This can be difficult for most clinicians
to evaluate, because it may be impos-
sible to compare different studies.
NOVEL METHODS OF RISK
ASSESSMENT  
The standard and most important prac-
tice management tool is to use global
risk assessment to determine a per-
son’s risk, as discussed above.
In future non-invasive imaging and
novel serum markers may be used to
measure and monitor atherosclerosis
to identify persons who may benefit
from aggressive primary prevention.
• Exercise ECG testing.In
asymptomatic people exercise ECG
testing can cause too many false-
positives, making it unsuitable as a
widespread population screening tool.
However, a positive stress ECG at low
workload in asymptomatic men is




about whether exercise testing should
be performed in asymptomatic
individuals; however, many will do this
test in asymptomatic persons with
multiple risk factors.  Those with a
positive test, male or female, should
be referred for specialist evaluation.
In asymptomatic people
exercise ECG testing can
cause too many false-posi-
tives, making it unsuitable
as a widespread popula-
tion screening tool.
• Magnetic resonance coronary
angiography. This is currently an 
experimental tool, but has the poten-
tial to image atherosclerotic plaque
composition and size.
• Ankle-brachial blood pressure
index. This requires a blood pressure
cuff and a Doppler ultrasonic sensor to
identify lower extremity, peripheral
arterial disease in asymptomatic per-
sons.
• B-mode ultrasound. This is used
to visualise intima-media thickness
(IMT) in the lumen of selected arteries,
e.g. carotid.  Clinical data from two
studies in more than 15 000 patients
demonstrated that the higher the IMT
the greater the subsequent risk of MI
or stroke.12,13
• Novel serum markers. New
lipid fractions such as apolipoprotein
B and others have the potential to
increase the precision of risk predic-
tion, but await large trials.  C-reactive
protein (CRP) is an established marker
for low-grade systemic inflammation,
which is a reflection of elevated pro-
inflammatory cytokines.  Useful assays
are those for highly sensitive CRP (hs-
CRP), which measures CRP levels pre-
viously thought to be within normal
range.
In the Physician’s Health Study,14 per-
sons in the highest quartile of hs-CRP
at baseline had a two-fold higher risk
of stroke, and a three-fold higher risk
of MI. Homocysteinaemia has been
shown to correlate with CHD risk in
cross-sectional studies, but data are
conflicting in prospective studies.
Patients with high serum levels of
homocysteine should be advised to
consume the recommended dietary
allowance of folic acid.
• Kidney dysfunction. The
diagnosis of deranged renal function,
i.e. increase in serum urea and
creatinine, decrease in creatinine
clearance, and presence of proteinuria
(> 300 mg/day) or microalbuminuria
(30 - 300 mg/day), has been linked to
an increase in cardiovascular disease
and cardiac mortality.  Microalbumi-
nuria represents the renal expression of 
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Risk factors for atherosclerotic heart disease
Risk factors for instability of plaque and plaque rupture
Acute cardiovascular event
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Fig.2. Pathway of cardiovascular disease.
ERRATUM - OCTOBER CME
In the article 'Screening for microvascular complications of diabetes mellitus: missed opportunities' by Professor W F Mollentze, there was
an error in Table IV, p 586. The units of the urinary albumin excretion rates in the random and overnight samples should have been 30 -
300 µg/min and 20 -200 µg/min respectively for microalbuminuria. For macroalbuminuria they should have been >300 µg/min and
>200 µg/min.
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Global risk assessment using the classic risk factors of blood pressure, total cholesterol, high-density lipoprotein, smoking
and diabetes mellitus is necessary in patient evaluation. It can predict future cardiovascular events.
Various new methods of risk assessment are being developed, e.g. hs-CRP.
Individuals at high risk of developing heart failure, e.g those with longstanding hypertension, previous MI, type 2 dia-
betes, should be targeted for evaluation and early heart failure treatment.
IN A NUTSHELL   
Microalbuminuria repre-
sents the renal expression
of a generalised vascular
disorder characterised by
increased endothelial per-
meability, which is the link
between albuminuria and
increased risk of cardiovas-
cular disease.
From Fig. 2 it is clear that
the usual risk factors for
cardiovascular disease also
determine the risk of devel-
oping heart failure. these
cases comprise up to 40%
of individuals who may
develop heart failure.
a generalised vascular disorder
characterised by increased endothelial
permeability, which is the link between
albuminuria and increased risk of
cardiovascular disease.
In Fig. 2 an algorithm of risk is
presented, starting with risk factors for
atherosclerosis and completing the
pathogenetic pathway to include heart
failure.
Risk of plaque rupture
Very little information is available on
useful clinical risk factors that could
identify the individual who has a high
risk of developing plaque rupture with
consequent acute coronary syndrome.
Systemic inflammatory changes, and a
high hs-CRP, may be indicative of
plaque rupture.  Higher blood
pressure, cholesterol levels and resting
pulse rate could indicate a higher risk
of plaque rupture, but much more
research is needed to find useful
clinical risk factors to predict this.
Risk factors for heart failure
From Fig. 2 it is clear that the usual
risk factors for cardiovascular disease
also determine the risk of developing
heart failure. These cases comprise up
to 40% of individuals who may devel-
op heart failure.  From the Framing-
ham Heart Study the lifetime risk of
developing heart failure is ± 20% for
both men and women.15 The short-term
risk for younger people is substantially
lower.  Effective prevention of heart
failure requires early detection by the
doctor and the early correction of pre-
disposing conditions and risk factors.
High-risk asymptomatic persons with
longstanding hypertension, previous
MI, left ventricular hypertrophy, car-
diomegaly on chest radiographs, dia-
betes mellitus and valvular disease
with a heart murmur must be identified
and investigated for the presence of
early left ventricular dysfunction.
These high-risk patients need to be tar-
geted for early treatment with e.g.
ACE inhibitors, which have been
shown to reduce the development of
clinical heart failure. 
For preventive strategies to be fully
effective against heart failure, they
have to be implemented throughout the
lifetime of the individual.
CONCLUSION
Various methods have improved our
risk assessment of individuals, which
hopefully will contribute to better
management and ultimately to a lower
incidence of atherosclerotic disease.
For the practitioner, aggressive
management of established
cardiovascular risk factors is still the
best option for high-risk individuals.
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